Opaleye Management’s Vaxcyte PCVX Stock Holding History

Opaleye Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-75,000	Closed	-$6.14M	–	52
2024 Q4	$6.14M	Sell	75,000 -10,000	-12%	-$993K	1.07%	20
2024 Q3	$9.71M	Hold	85,000	–	–	1.62%	14
2024 Q2	$6.42M	Hold	85,000	–	–	1.47%	22
2024 Q1	$5.81M	Sell	85,000 -5,000	-6%	-$346K	1.27%	26
2023 Q4	$5.65M	Hold	90,000	–	–	1.5%	19
2023 Q3	$4.59M	Sell	90,000 -87,000	-49%	-$4.29M	1.49%	17
2023 Q2	$8.84M	Hold	177,000	–	–	2.11%	11
2023 Q1	$6.63M	Hold	177,000	–	–	1.99%	14
2022 Q4	$8.49M	Sell	177,000 -13,000	-7%	-$510K	2.95%	8
2022 Q3	$4.56M	Hold	190,000	–	–	1.88%	18
2022 Q2	$4.13M	Sell	190,000 -21,000	-10%	-$486K	1.86%	18
2022 Q1	$5.1M	Sell	211,000 -104,800	-33%	-$2.29M	1.58%	21
2021 Q4	$7.51M	Sell	315,800 -37,600	-11%	-$874K	1.59%	23
2021 Q3	$8.97M	Sell	353,400 -4,400	-1%	-$107K	1.67%	20
2021 Q2	$8.05M	Hold	357,800	–	–	1.34%	25
2021 Q1	$7.07M	Buy	357,800 +22,600	+7%	+$569K	1.04%	30
2020 Q4	$8.91M	Buy	335,200 +22,200	+7%	+$825K	1.16%	25
2020 Q3	$15.5M	Buy	+313,000	New	+$12.5M	3.02%	11

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Opaleye Management's PCVX Position: Q1 2025 in Review

Opaleye Management sold out of Vaxcyte (PCVX) in Q1 2025, closing a stake of 75,000 shares — an estimated $6.14M sold.

Opaleye Management first reported a position in PCVX in Q3 2020 and held it in 18 quarters. The position peaked at $15.5M in Q3 2020. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

Opaleye Management reported no remaining Vaxcyte position as of Q1 2025 after selling out during the quarter.
Opaleye Management sold 75,000 Vaxcyte shares in Q1 2025, an estimated $6.14M.
Opaleye Management first reported a position in Vaxcyte in Q3 2020 and held it in 18 quarters.
Opaleye Management's Vaxcyte position peaked at $15.5M in Q3 2020.
315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on Opaleye Management's 13F filing for Q1 2025, filed 15 May 2025.